Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
2.160
-0.170 (-7.30%)
At close: Jan 30, 2026, 4:00 PM EST
2.150
-0.010 (-0.46%)
After-hours: Jan 30, 2026, 7:24 PM EST
Coherus Oncology Revenue
Coherus Oncology had revenue of $11.57M in the quarter ending September 30, 2025, with 91.19% growth. This brings the company's revenue in the last twelve months to $277.73M, up 152.07% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.
Revenue (ttm)
$277.73M
Revenue Growth
+152.07%
P/S Ratio
0.90
Revenue / Employee
$1,757,772
Employees
158
Market Cap
261.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| OmniAb | 21.09M |
| Armata Pharmaceuticals | 5.05M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
| Abeona Therapeutics | 400.00K |
| Avalo Therapeutics | 192.00K |
CHRS News
- 17 days ago - Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 25 days ago - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - GlobeNewsWire
- 5 weeks ago - Coherus Oncology: A Two-Pronged March With Mid-2026 Implications - Seeking Alpha
- 7 weeks ago - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - GlobeNewsWire
- 2 months ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody - GlobeNewsWire